EVERMINE50
Breakthrough in DES Technology:
- Ultra-low strut thickness of 50μm for promoting early vascular healing
- Variable strut width and variable crown design to ensure adequate radial strength of 1.1bar*
- Hybrid cell stent design: Open cells in the middle of the stent for side-branch access and closed cell design on ends for optimal scaffolding and conformability
- Clinically established drug everolimus with biodegradable polymer for proven clinical safety & long term efficacy
*Bench test data on file at Meril Life Sciences
- >500 ALL COMER PATIENTS STUDIED IN 3 CLINICAL STUDIES WITH FOLLOW-UP UP TO 1 YEAR. ONGOING ROBUST CLINICAL TRIAL PROGRAMME.
- 0% STENT THROMBOSIS AT 6 MONTHS AND 1 YEAR IN ALL COMER PATIENT POPULATION
- LOW MACE RATE OF <2% AT 1 YEAR